scholarly journals Intimate Attachment of Escherichia coli O157:H7 to Urinary Bladder Epithelium in the Gnotobiotic Piglet Model

2020 ◽  
Vol 8 (2) ◽  
pp. 263 ◽  
Author(s):  
Rodney A. Moxley ◽  
Tom W. Bargar ◽  
Stephen D. Kachman ◽  
Diane R. Baker ◽  
David H. Francis
Keyword(s):  
Escherichia Coli ◽  
Urinary Bladder ◽  
Enterohemorrhagic Escherichia Coli ◽  
Post Inoculation ◽  
Bladder Epithelium ◽  
Fecal Shedding ◽  
E Coli ◽  
Gnotobiotic Piglet ◽  
Immunohistochemical Evidence ◽  
Tract Infections

Enterohemorrhagic Escherichia coli (EHEC), a pathogenic subset of Shiga toxin-producing E. coli (STEC), is an important cause of hemorrhagic colitis and hemolytic–uremic syndrome (HUS), and a rare cause of urinary tract infections (UTIs) with associated HUS. EHEC strains attach intimately to intestinal epithelium with formation of actin pedestals (attaching-effacing (A/E) lesions); however, the mechanism of EHEC attachment to the uroepithelium is unknown. We conducted a retrospective study on archived urinary bladder specimens from gnotobiotic piglets that naturally developed cystitis associated with EHEC O157:H7 infection following oral inoculation and fecal shedding. Paraffin-embedded bladder tissues from three piglets with cystitis and immunohistochemical evidence of EHEC O157:H7 adherence to the uroepithelium were processed for and examined by transmission electron microscopy. EHEC O157:H7 bacteria were found in one of three piglets, intimately attached to pedestals on the apical surfaces of the superficial urothelium (umbrella cells). Cystitis was significantly associated with the length of survival of the piglets post-inoculation (p = 0.0339; estimated odds ratio = 2.6652). This is the first report of E. coli causing A/E-like lesions in the uroepithelium, and also evidence of the utility of the gnotobiotic piglet as a model for studies of the pathogenesis of EHEC UTIs.

scholarly journals Correction: Moxley, R.A., et al. Intimate Attachment of Escherichia coli O157:H7 to Urinary Bladder Epithelium in the Gnotobiotic Piglet Model. Microorganisms 2020, 8, 263

2020 ◽  
Vol 8 (12) ◽  
pp. 2016
Author(s):  
Rodney A. Moxley ◽  
Tom W. Bargar ◽  
Stephen D. Kachman ◽  
Diane R. Baker ◽  
David H. Francis
Keyword(s):  
Escherichia Coli ◽  
Urinary Bladder ◽  
Escherichia Coli O157 ◽  
Bladder Epithelium ◽  
Gnotobiotic Piglet

The authors wish to make the following corrections to this paper [...]

scholarly journals Rectal Carriage of Enterohemorrhagic Escherichia coli O157 in Slaughtered Cattle

2005 ◽  
Vol 71 (1) ◽  
pp. 93-97 ◽  
Author(s):  
J. Christopher Low ◽  
Iain J. McKendrick ◽  
Caroline McKechnie ◽  
David Fenlon ◽  
Stuart W. Naylor ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
Enterohemorrhagic Escherichia Coli ◽  
Fecal Excretion ◽  
Escherichia Coli O157 ◽  
Fecal Shedding ◽  
E Coli ◽  
Mucosal Surfaces ◽  
Human Illness ◽  
Experimental Findings ◽  
High Level

ABSTRACT Escherichia coli O157:H7 is an important cause of diarrhea, hemorrhagic colitis, and potentially fatal human illness. Cattle are considered a primary reservoir of infection, and recent experimental evidence has indicated that the terminal rectum is the principal site of bacterial carriage. To test this finding in naturally colonized animals, intact rectum samples from 267 cattle in 24 separate lots were obtained immediately after slaughter, and fecal material and mucosal surfaces were cultured for E. coli O157 by direct and enrichment methods. Two locations, 1 and 15 cm proximal to the recto-anal junction, were tested. In total, 35 animals were positive for E. coli O157 at at least one of the sites and 232 animals were negative as determined by all tests. The frequency of isolation and the numbers of E. coli O157 cells were higher at the site closer to the recto-anal junction, confirming our previous experimental findings. We defined low- and high-level carriers as animals with E. coli O157 levels of <1 � 103 CFU g−1 or <1 � 103 CFU ml−1 and animals with E. coli O157 levels of ≥1 � 103 CFU g−1 or ≥1 � 103 CFU ml−1 in feces or tissues, respectively. High-level carriage was detected in 3.7% of the animals (95% confidence interval, 1.8 to 6.8%), and carriage on the mucosal surface of the terminal rectum was associated with high-level fecal excretion. In summary, our results support previous work demonstrating that the mucosal epithelium in the bovine terminal rectum is an important site for E. coli O157 carriage in cattle. The data also support the hypothesis that high-level fecal shedding (≥1 � 103 CFU g of feces−1) of enterohemorrhagic E. coli O157 results from colonization of this site.

Fecal Shedding of Enterohemorrhagic Escherichia coli in Weaned Calves following Treatment with Probiotic Escherichia coli

2003 ◽  
Vol 66 (7) ◽  
pp. 1184-1189 ◽  
Author(s):  
SUZANA TKALCIC ◽  
TONG ZHAO ◽  
BARRY G. HARMON ◽  
MICHAEL P. DOYLE ◽  
CATHY A. BROWN ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
Competitive Exclusion ◽  
No Reduction ◽  
Enterohemorrhagic Escherichia Coli ◽  
Probiotic Bacteria ◽  
Peroral Administration ◽  
Fecal Shedding ◽  
E Coli ◽  
Large Populations ◽  
Total Bacteria

The fecal shedding and pathogenicity of enterohemorrhagic E. coli (EHEC) O26:H11, EHEC O111:NM, and EHEC O157:H7 in weaned calves (8 to 10 weeks of age) were compared with and without treatment with a three-strain mixture of probiotic bacteria (competitive-exclusion E. coli). Three groups of 12 calves were each perorally given a five-strain mixture of one of the EHEC serotypes (1010 CFU of total bacteria per calf). Seventy-two hours later, six calves from each group were each administered 1010 CFU of probiotic bacteria. None of the EHEC serotypes caused significant clinical disease, although a few calves developed mild transient diarrhea or pyrexia. Gross or microscopic lesions attributable to EHEC were not detected in control or probiotic-treated calves at necropsy. For probiotic-treated calves given E. coli O157:H7 and for probiotic-treated calves given E. coli O111:NM, fecal shedding was reduced compared with that for untreated calves. For the probiotic-treated calves given E. coli O157:H7, the reductions in fecal shedding on days 8, 12, 14, 16, 20, 22, 28, and 30 after peroral administration were statistically significant (P &lt; 0.05). For probiotic-treated calves given E. coli O111:NM, there were statistically significant reductions (P &lt; 0.05) in fecal shedding on days 6, 8, 10, and 12. In contrast, there was no reduction in fecal shedding for calves administered E. coli O26:H11 and treated with the probiotic bacteria. In fact, calves in both the treated and the nontreated groups continued to shed large populations of E. coli O26:H11 throughout the 32-day trial. At necropsy, E. coli O157:H7 was isolated from five of six untreated calves and from only two of six probiotic-treated calves. E. coli O111:NM was isolated from four of six untreated calves at necropsy and from two of six probiotic-treated calves. However, E. coli O26:H11 was isolated from five of six untreated calves and from all six probiotic-treated calves. The results obtained in this study indicate that probiotic E. coli substantially reduced or eliminated fecal shedding of E. coli O157:H7 and E. coli O111:NM 8 to 30 days and 6 to 12 days after the administration of the probiotic culture, respectively, and reduced the persistence of E. coli O157:H7 in the gastrointestinal tract at necropsy (31 to 33 days after the administration of the probiotic culture). The probiotic E. coli did not reduce fecal shedding or gastrointestinal persistence of E. coli O26:H11.

Pathogenicity of Enterohemorrhagic Escherichia coli in Neonatal Calves and Evaluation of Fecal Shedding by Treatment with Probiotic Escherichia coli

2003 ◽  
Vol 66 (6) ◽  
pp. 924-930 ◽  
Author(s):  
TONG ZHAO ◽  
SUZANA TKALCIC ◽  
MICHAEL P. DOYLE ◽  
BARRY G. HARMON ◽  
CATHY A. BROWN ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
Untreated Control ◽  
Enterohemorrhagic Escherichia Coli ◽  
Probiotic Bacteria ◽  
Peroral Administration ◽  
Control Group ◽  
Fecal Shedding ◽  
E Coli ◽  
Significant Difference ◽  
Neonatal Calves

The pathogenicity and fecal shedding of enterohemorrhagic Escherichia coli (EHEC) O26:H11, O111:NM, and O157:H7 were compared in calves (&lt;1 week of age) with or without prior treatment with probiotic bacteria (competitive exclusion E. coli). Three groups of 12 to 14 calves were used for these treatments. Half of the calves in each group were perorally administered 1010 CFU of probiotic bacteria per calf, and, 2 days thereafter, 108 CFU of a five-strain mixture with one of the three EHEC serotypes per calf were administered to each calf. None of the EHEC serotypes caused clinical disease, and neither gross nor microscopic lesions attributable to EHEC were detected in control or probiotic-treated calves at necropsy. In calves administered E. coli O157:H7, fecal shedding was greatly reduced (&gt;6 log10 CFU/g) by 8 days after administration, and there was no significant difference (P &gt; 0.05) in fecal shedding of E. coli O157:H7 between probiotic-treated and untreated control groups at that time. In contrast, control calves perorally administered E. coli of serotypes O111:NM or O26:H11 continued to shed substantial populations (102.1 to 106 CFU/g of feces and 102.5 to 104.9 CFU/g of feces, respectively) throughout 7 days postadministrationof EHEC. In both groups administered either E. coli O111:NM or O26:H11, significantly less (P &lt; 0.05) EHEC was isolated from feces at 7 days postadministration of EHEC and at necropsy from the probiotic-treated group than from the untreated control group. Overall, neonatal calves shed in the feces from 1 to 7 days following peroral administration of EHEC greater populations of E. coli O111:NM and O26:H11 than E. coli O157:H7. In addition, treatment of calves with probiotic E. coli reduced fecal shedding of E. coli O111:NM and O26:H11 in most calves.

scholarly journals Characterization of Urinary Tract Infection-Associated Shiga Toxin-Producing Escherichia coli

2014 ◽  
Vol 82 (11) ◽  
pp. 4631-4642 ◽  
Author(s):  
Francisco Toval ◽  
Roswitha Schiller ◽  
Iris Meisen ◽  
Johannes Putze ◽  
Ivan U. Kouzel ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
Urinary Tract ◽  
Urinary Bladder ◽  
Shiga Toxin ◽  
Infection Model ◽  
Content Type ◽  
E Coli ◽  
Virulence Markers ◽  
T24 Cells ◽  
Tract Infections

ABSTRACTEnterohemorrhagicEscherichia coli(EHEC), a subgroup of Shiga toxin (Stx)-producingE. coli(STEC), is a leading cause of diarrhea and hemolytic-uremic syndrome (HUS) in humans. However, urinary tract infections (UTIs) caused by this microorganism but not associated with diarrhea have occasionally been reported. We geno- and phenotypically characterized three EHEC isolates obtained from the urine of hospitalized patients suffering from UTIs. These isolates carried typical EHEC virulence markers and belonged to HUS-associatedE. coli(HUSEC) clones, but they lacked virulence markers typical of uropathogenicE. coli. One isolate exhibited a localized adherence (LA)-like pattern on T24 urinary bladder epithelial cells. Since the glycosphingolipids (GSLs) globotriaosylceramide (Gb3Cer) and globotetraosylceramide (Gb4Cer) are well-known receptors for Stx but also for P fimbriae, a major virulence factor of extraintestinal pathogenicE. coli(ExPEC), the expression of Gb3Cer and Gb4Cer by T24 cells and in murine urinary bladder tissue was examined by thin-layer chromatography and mass spectrometry. We provide data indicating that Stxs released by the EHEC isolates bind to Gb3Cer and Gb4Cer isolated from T24 cells, which were susceptible to Stx. All three EHEC isolates expressedstxgenes upon growth in urine. Two strains were able to cause UTI in a murine infection model and could not be outcompeted in urinein vitroby typical uropathogenicE. coliisolates. Our results indicate that despite the lack of ExPEC virulence markers, EHEC variants may exhibit in certain suitable hosts, e.g., in hospital patients, a uropathogenic potential. The contribution of EHEC virulence factors to uropathogenesis remains to be further investigated.

scholarly journals Avian Pathogenic Escherichia coli (APEC): An Overview of Virulence and Pathogenesis Factors, Zoonotic Potential, and Control Strategies

Pathogens ◽  
2021 ◽  
Vol 10 (4) ◽  
pp. 467
Author(s):  
Dipak Kathayat ◽  
Dhanashree Lokesh ◽  
Sochina Ranjit ◽  
Gireesh Rajashekara
Keyword(s):  
Escherichia Coli ◽  
Current Status ◽  
Neonatal Meningitis ◽  
Clear Understanding ◽  
Zoonotic Potential ◽  
Secretion Systems ◽  
Avian Pathogenic Escherichia Coli ◽  
E Coli ◽  
Pathogenic Escherichia Coli ◽  
Tract Infections

Avian pathogenic Escherichia coli (APEC) causes colibacillosis in avian species, and recent reports have suggested APEC as a potential foodborne zoonotic pathogen. Herein, we discuss the virulence and pathogenesis factors of APEC, review the zoonotic potential, provide the current status of antibiotic resistance and progress in vaccine development, and summarize the alternative control measures being investigated. In addition to the known virulence factors, several other factors including quorum sensing system, secretion systems, two-component systems, transcriptional regulators, and genes associated with metabolism also contribute to APEC pathogenesis. The clear understanding of these factors will help in developing new effective treatments. The APEC isolates (particularly belonging to ST95 and ST131 or O1, O2, and O18) have genetic similarities and commonalities in virulence genes with human uropathogenic E. coli (UPEC) and neonatal meningitis E. coli (NMEC) and abilities to cause urinary tract infections and meningitis in humans. Therefore, the zoonotic potential of APEC cannot be undervalued. APEC resistance to almost all classes of antibiotics, including carbapenems, has been already reported. There is a need for an effective APEC vaccine that can provide protection against diverse APEC serotypes. Alternative therapies, especially the virulence inhibitors, can provide a novel solution with less likelihood of developing resistance.

scholarly journals Antimicrobial activity of Syzygium aromaticum L. essential oil on extended-spectrum beta-lactamases-producing Escherichia coli

2020 ◽  
Vol 44 (1) ◽  
Author(s):  
E. L. Mejía-Argueta ◽  
J. G. Santillán-Benítez ◽  
M. M. Canales-Martinez ◽  
A. Mendoza-Medellín
Keyword(s):  
Escherichia Coli ◽  
Essential Oil ◽  
Genetic Material ◽  
Gastrointestinal Diseases ◽  
Syzygium Aromaticum ◽  
Antibiotic Resistant ◽  
Plant Essential Oils ◽  
E Coli ◽  
Extended Spectrum ◽  
Tract Infections

Abstract Background To test the antimicrobial potential of clove essential oil that has been less investigated on antimicrobial-resistant organisms (extended-spectrum β-lactamase-ESBL-producing Escherichia coli), we collected 135 ESBL-producing Escherichia coli strains given that E. coli is the major organism increasingly isolated as a cause of complicated urinary and gastrointestinal tract infections, which remains an important cause of therapy failure with antibiotics for the medical sector. Then, in this study, we evaluated the relationship between the antibacterial potential activity of Syzygium aromaticum essential oil (EOSA) and the expression of antibiotic-resistant genes (SHV-2, TEM-20) in plasmidic DNA on ESBL-producing E. coli using RT-PCR technique. Results EOSA was obtained by hydrodistillation. Using Kirby-Baüer method, we found that EOSA presented a smaller media (mean = 15.59 mm) in comparison with chloramphenicol (mean = 17.73 mm). Thus, there were significant differences (p < 0.0001). Furthermore, EOSA had an antibacterial activity, particularly on ECB132 (MIC: 10.0 mg/mL and MBC: 80.0 mg/mL), and a bacteriostatic effect by bactericidal kinetic. We found that the expression of antibiotic-resistant gene blaTEM-20 was 23.52% (4/17 strains) and no expression of blaSHV-2. EOSA presented such as majority compounds (eugenol, caryophyllene) using the GC–MS technique. Conclusions Plant essential oils and their active ingredients have potentially high bioactivity against a different target (membranes, cytoplasm, genetic material). In this research, EOSA might become an important adjuvant against urinary and gastrointestinal diseases caused by ESBL-producing E. coli.

scholarly journals 1671. Diagnosis and management of Escherichia coli bacteriuria at a Veterans Affairs hospital

2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S821-S821
Author(s):  
Niyati H Shah ◽  
Brooke K Decker ◽  
Brooke K Decker ◽  
Gaetan Sgro ◽  
Monique Y Boudreaux-Kelly ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
Antibiotic Treatment ◽  
High Yield ◽  
Comorbid Conditions ◽  
Provider Education ◽  
Transmitted Infection ◽  
Physician Practices ◽  
E Coli ◽  
Diagnosis And Management ◽  
Tract Infections

Abstract Background The IDSA recommends against screening for and treating ASB in all patients except for those pregnant or undergoing urologic procedures. Nevertheless, antibiotic treatment of ASB is widespread. We conducted a retrospective analysis of physician practices in diagnosis and management of Escherichia coli (E. coli) ASB in a male Veteran population, and compared outcomes in ASB patients treated or not treated with antibiotics. Methods Patients with an E. coli positive urine culture during an ED visit or inpatient admission from 01/2017 to 12/2017 were screened. Patients admitted to the intensive care unit or diagnosed with a sexually transmitted infection, pyelonephritis, prostatitis, or epididymitis/orchitis were excluded. A total of 163 patients were included. Demographics, clinical comorbidities and severity of illness, and outcomes were compared in ASB patients managed with or without antibiotics. ANOVA and Chi-square or Fisher’s exact tests were utilized for comparing measurements. Results ASB was present in 92/163 patients. The majority (74%) of these patients were given antibiotics. Regardless of qSOFA score or alternate infection, there were no significant differences in outcomes between ASB patients treated or not treated with antibiotics: 3-month mortality (15% vs 21%; p = 0.53), emergence of newly resistant bacterial pathogens (7% vs 13%; p = 0.43), recurrent urinary tract infections (61% vs 50%; p = 0.72), clearance of urinary pathogens (75% vs 58%; p = 0.45), length of hospital stay (7 vs 6 days, p = 0.67). Factors that were predictive of physician treatment of ASB included patient comorbid conditions such as benign prostatic hyperplasia, pyuria, and the absence of hematuria. The incidence of adverse events with antibiotic treatment of ASB was low. Conclusion The rate of antibiotic treatment of E. coli ASB in male veterans is high. Outcomes do not differ among ASB patients managed with or without antibiotics. Future studies examining outcomes in patients prescribed antibiotics for multiple episodes of ASB may yield differences, particularly in emergence of resistant pathogens. Focusing on patients with comorbid conditions who are not critically ill would be a high yield target for provider education to reduce ASB treatment. Disclosures All Authors: No reported disclosures

Bacteriophages reduce Escherichia coli O157:H7 levels in experimentally inoculated sheep

2009 ◽  
Vol 89 (2) ◽  
pp. 285-293 ◽  
Author(s):  
S J Bach ◽  
R P Johnson ◽  
K. Stanford ◽  
T A McAllister
Keyword(s):  
Escherichia Coli ◽  
Oral Administration ◽  
Coliform Bacteria ◽  
Escherichia Coli O157 ◽  
Fecal Shedding ◽  
Total Coliforms ◽  
E Coli ◽  
Oral Inoculation ◽  
Experimental Treatments ◽  
And Control

Bacteriophage biocontrol has potential as a means of mitigating the prevalence of Escherichia coli O157:H7 in ruminants. The efficacy of oral administration of bacteriophages for reducing fecal shedding of E. coli O157:H7 by sheep was evaluated using 20 Canadian Arcott rams (50.0 ± 3.0) housed in four rooms (n = 5) in a contained facility. The rams had ad libitum access to drinking water and a pelleted barley-based total mixed ration, delivered once daily. Experimental treatments consisted of administration of E. coli O157:H7 (O157), E. coli O157:H7+bacteriophages (O157+phage), bacteriophages (phage), and control (CON). Oral inoculation of the rams with 109 CFU of a mixture of four nalidixic acid-resistant strains of E. coli O157:H7 was performed on day 0. A mixture of 1010 PFU of bacteriophages P5, P8 and P11 was administered on days -2, -1, 0, 6 and 7. Fecal samples collected on 14 occasions over 21 d were analyzed for E. coli O157:H7, total E. coli, total coliforms and bacteriophages. Sheep in treatment O157+phage shed fewer (P < 0.05) E. coli O157:H7 than did sheep in treatment O157. Populations of total coliforms and total E. coli were similar (P < 0.05) among treatments, implying that bacteriophage lysis of non-target E. coli and coliform bacteria in the gastrointestinal tract did not occur. Bacteriophage numbers declined rapidly over 21 d, which likely reduced the chance of collision between bacteria and bacteriophage. Oral administration of bacteriophages reduced shedding of E. coli O157:H7 by sheep, but a delivery system that would protect bacteriophages during passage through the intestine may increase the effectiveness of this strategy as well as allow phage to be administered in the feed.Key words: Escherichia coli O157:H7, bacteriophage, sheep, environment, coliforms

scholarly journals Iron Acquisition of Urinary Tract Infection Escherichia coli Involves Pathogenicity in Caenorhabditis elegans

2021 ◽  
Vol 9 (2) ◽  
pp. 310
Author(s):  
Masayuki Hashimoto ◽  
Yi-Fen Ma ◽  
Sin-Tian Wang ◽  
Chang-Shi Chen ◽  
Ching-Hao Teng
Keyword(s):  
Escherichia Coli ◽  
Urinary Tract ◽  
Caenorhabditis Elegans ◽  
Large Scale ◽  
Iron Acquisition ◽  
Infection Model ◽  
High Throughput Analysis ◽  
E Coli ◽  
C Elegans ◽  
Tract Infections

Uropathogenic Escherichia coli (UPEC) is a major bacterial pathogen that causes urinary tract infections (UTIs). The mouse is an available UTI model for studying the pathogenicity; however, Caenorhabditis elegans represents as an alternative surrogate host with the capacity for high-throughput analysis. Then, we established a simple assay for a UPEC infection model with C. elegans for large-scale screening. A total of 133 clinically isolated E. coli strains, which included UTI-associated and fecal isolates, were applied to demonstrate the simple pathogenicity assay. From the screening, several virulence factors (VFs) involved with iron acquisition (chuA, fyuA, and irp2) were significantly associated with high pathogenicity. We then evaluated whether the VFs in UPEC were involved in the pathogenicity. Mutants of E. coli UTI89 with defective iron acquisition systems were applied to a solid killing assay with C. elegans. As a result, the survival rate of C. elegans fed with the mutants significantly increased compared to when fed with the parent strain. The results demonstrated, the simple assay with C. elegans was useful as a UPEC infectious model. To our knowledge, this is the first report of the involvement of iron acquisition in the pathogenicity of UPEC in a C. elegans model.

Sign in / Sign up

Export Citation Format

Share Document